stockrowUnited Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) EBITDA
United Therapeutics Corporation's EBITDA for fiscal 2025 was $1.6B, up 8.87% from $1.4B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.4B. Over the past ten years it has ranged from −$141.7M (fiscal 2019) to $1.6B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. United Therapeutics Corporation ranks 6th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.6B | 8.87% |
| FY2024 | $1.4B | 17.07% |
| FY2023 | $1.2B | 20.09% |
| FY2022 | $1.0B | 70.19% |
| FY2021 | $605.8M | (5.86%) |
| FY2020 | $643.5M | — |
| FY2019 | −$141.7M | — |
| FY2018 | $841.3M | (0.54%) |
| FY2017 | $845.9M | (22.63%) |
| FY2016 | $1.1B | 49.38% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $355.0M | 1.89% |
| Mar 2026 | $348.4M | (8.19%) |
| Dec 2025 | $379.5M | (7.53%) |
| Sep 2025 | $410.4M | 6.43% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $8.3B |
| HLN Haleon PLC Sponsored ADR compare | $4.3B |
| ZTS Zoetis Inc. compare | $4.0B |
| VTRS Viatris Inc. compare | $2.7B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $2.3B |
| UTHR United Therapeutics Corporation | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $976.5M |
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on UTHR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement